logo
Osaka bans public smoking ahead of Expo 2025

Osaka bans public smoking ahead of Expo 2025

CNN29-01-2025

One of Japan's biggest cities is 'beautifying' itself ahead of hosting the World Expo — not by planting flowers, but by banning cigarettes.
Osaka will soon host Expo 2025, which runs from April to October, with representatives from 158 countries and regions participating in talks, demonstrations and exhibitions.
The ban on public smoking, which took effect on January 27, includes roads, parks, plazas and other public places and applies not only to cigarettes, but also to vapes. Violators will be fined 1,000 yen (about $6).
'Osaka City will expand its no-smoking areas to cover the entire city to enhance safety, cleanliness and its image as an international tourist destination,' city officials announced in a statement earlier this month. 'This initiative aims not only to beautify the city but also to ensure a safe, secure and comfortable living environment for residents and visitors.'
Current national laws largely ban smoking in establishments such as restaurants, offices and public transportation, and some cities have bans in public places. It is also illegal for people under the age of 20 to smoke and buy tobacco.
However, throughout Japan, it's common for airports, train stations and other public buildings to have dedicated smoking rooms.
The World Health Organization estimates that the number of Japanese people who use tobacco and smoke cigarettes has roughly halved over the past two decades, declining from around 32% in 2000 to around 16% in 2022.
A 2022 survey by Japan's Ministry of Health (MOH) found that 14.8% of adults smoke. The MOH has set a goal of lowering the national smoking rate to 12%.
Compare that to the United States, where in 2022, 19.8% — nearly 1 in 5 — US adults reported current tobacco product use, according to the Centers for Disease Control and Prevention.
After announcing the strict new rules around public tobacco use, Osaka's local government created a map showing where in the city it is still okay to light up.
Similar anti-smoking measures have been implemented in other parts of Japan, including in Tokyo ahead of the 2020 Olympics, which have remained in place ever since.
Some public figures have even been called out in the past for smoking underage.
Arguably the most famous recent example was Shoko Miyata, captain of Japan's women's gymnastics team. Miyata withdrew from the Summer Olympics in Paris last year after admitting to smoking and drinking. She was 19 at the time.
The six-month Expo 2025 runs from April 13 until October 13. The city has spent 164.7 billion yen ($1.16 billion) on the event, including major urban infrastructure projects.
CNN Travel named the Kansai region — which includes Osaka — as one of its 25 places to visit in 2025.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Cardio Diagnostics Secures Japanese Patent for AI-Driven Cardiovascular Disease Detection Technology
Cardio Diagnostics Secures Japanese Patent for AI-Driven Cardiovascular Disease Detection Technology

Business Wire

time39 minutes ago

  • Business Wire

Cardio Diagnostics Secures Japanese Patent for AI-Driven Cardiovascular Disease Detection Technology

CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings Inc. (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, today announced that the Japan Patent Office has issued a patent for another set of biomarkers in the company's intellectual property portfolio. The patent, titled 'Compositions and Methods for Detecting Predisposition to Cardiovascular Disease,' (Japanese Patent No. 7672192) is exclusively licensed to Cardio Diagnostics from the University of Iowa Research Foundation (UIRF) and names Cardio Diagnostics' founders Meesha Dogan, Ph.D., Chief Executive Officer, and Robert Philibert, MD, Ph.D., Chief Medical Officer, as inventors. The Japanese patent further strengthens Cardio Diagnostics' global IP strategy and adds to its robust portfolio of issued patents in the United States, Europe, Australia, India, and China, covering core technologies that helped yield the Company's clinical solutions. 'Receiving this patent in Japan marks a critical milestone in our mission to globalize our precision cardiovascular medicine platform,' said Meesha Dogan, Ph.D., CEO of Cardio Diagnostics. 'As cardiovascular disease continues to rise in prevalence worldwide, the ability to offer AI-powered, methylation- and genetics-based diagnostics in international markets like Japan represents a major step forward in improving early detection and prevention of heart disease.' 'We are proud to support this important innovation from the University of Iowa ecosystem,' said Marie Kerbeshian, Ph.D., Executive Director of the UIRF. 'Cardio Diagnostics continues to demonstrate the global relevance of its technology, and we look forward to the impact it will have in advancing cardiovascular medicine across borders.' The Japanese patent protects Cardio Diagnostics' novel methods and compositions that enable the detection of cardiovascular disease risk and presence using epigenetic and genetic biomarkers interpreted through advanced machine learning algorithms. This issuance underscores the global applicability of the Company's pioneering approach to heart disease prevention. As part of its expanding IP footprint, Cardio Diagnostics is committed to delivering innovative, data-driven solutions that empower healthcare providers and patients with actionable insights for cardiovascular health, now on a global scale. About Cardio Diagnostics Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine ('Core Technology') for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit Forward-Looking Statements Certain statements and information included in this press release constitute 'forward-looking statements' within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases 'will', 'will likely result,' 'expected to,' 'will continue,' 'anticipated,' 'estimate,' 'projected,' 'intend,' 'goal,' or similar expressions are intended to identify 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on results are discussed in the Current Report on Form 10-K for the period ended in December 31, 2024, and Form 10-Q for the period ended in March 31, 2025, under the heading 'Risk Factors' in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release.

Why has there been a global surge of new Covid variant NB.1.8.1?
Why has there been a global surge of new Covid variant NB.1.8.1?

Yahoo

time8 hours ago

  • Yahoo

Why has there been a global surge of new Covid variant NB.1.8.1?

India is the latest country to report a surge in new Covid cases, as the latest variant, NB.1.8.1, spreads across the globe. Cases have now been reported in Asian countries such as Thailand, Indonesia and China, while the UK Health Security Agency recorded the first 13 cases in England last week. But the true numbers are unlikely to be known, given the significant decrease in the number of people testing compared to the figures seen during the global pandemic five years ago. NB.1.8.1 stemmed from the Omicron variant and was first detected in January this year. It has quickly spread across China and Hong Kong, and has now been recorded in several states across the United States and Australia. By late April, NB.1.8.1 comprised about 10.7 per cent of submitted sequences globally, according to the World Health Organization (WHO). This rose from just 2.5 per cent a month before. The WHO declared the NB.1.8.1 strain a 'variant under monitoring' on 23 May, which means scientists believe it could potentially affect the behaviour of the virus. Lara Herrero, a virologist from Griffith University in Australia, suspects that NB.1.8.1 spreads more easily than other variants. 'Using lab-based models, researchers found NB.1.8.1 had the strongest binding affinity to the human ACE2 receptor of several variants tested, suggesting it may infect cells more efficiently than earlier strains,' Dr Herrero wrote last month in The Conversation. Dr Chun Tang, GP at UK private healthcare centre Pall Mall Medical, said: 'NB.1.8.1 isn't too different from the Omicron variant, but it does have some tweaks to its spike protein, which might make it spread a bit more easily or slip past some of our existing immunity. 'That said, early signs suggest it doesn't seem to cause more serious illness, but of course, we're still learning more about it.' 'Its spread has been identified in around 22 countries,' said Dr Naveed Asif, GP at The London General Practice. 'The WHO assesses the additional risk to the global public as currently low, and existing Covid-19 vaccines are considered effective in preventing severe disease.' However, the 'Nimbus' variant, as it has been dubbed, does appear to be more transmissible than previous strains, with notable increases reported in India, Hong Kong, Singapore and Thailand, notes Dr Asif. Common symptoms of Nimbus include a severe sore throat, fatigue, mild cough, fever, muscle aches and congestion. It has also been reported that some patients have experienced gastrointestinal symptoms such as nausea and diarrhoea. Healthcare experts have stressed, however, that there is no evidence that the new strain is more deadly or serious than previous variants, and that current Covid vaccines are expected to remain effective and protect anyone infected from severe illness.

Why has there been a global surge of new Covid variant NB.1.8.1?
Why has there been a global surge of new Covid variant NB.1.8.1?

Yahoo

time9 hours ago

  • Yahoo

Why has there been a global surge of new Covid variant NB.1.8.1?

India is the latest country to report a surge in new Covid cases, as the latest variant, NB.1.8.1, spreads across the globe. Cases have now been reported in Asian countries such as Thailand, Indonesia and China, while the UK Health Security Agency recorded the first 13 cases in England last week. But the true numbers are unlikely to be known, given the significant decrease in the number of people testing compared to the figures seen during the global pandemic five years ago. NB.1.8.1 stemmed from the Omicron variant and was first detected in January this year. It has quickly spread across China and Hong Kong, and has now been recorded in several states across the United States and Australia. By late April, NB.1.8.1 comprised about 10.7 per cent of submitted sequences globally, according to the World Health Organization (WHO). This rose from just 2.5 per cent a month before. The WHO declared the NB.1.8.1 strain a 'variant under monitoring' on 23 May, which means scientists believe it could potentially affect the behaviour of the virus. Lara Herrero, a virologist from Griffith University in Australia, suspects that NB.1.8.1 spreads more easily than other variants. 'Using lab-based models, researchers found NB.1.8.1 had the strongest binding affinity to the human ACE2 receptor of several variants tested, suggesting it may infect cells more efficiently than earlier strains,' Dr Herrero wrote last month in The Conversation. Dr Chun Tang, GP at UK private healthcare centre Pall Mall Medical, said: 'NB.1.8.1 isn't too different from the Omicron variant, but it does have some tweaks to its spike protein, which might make it spread a bit more easily or slip past some of our existing immunity. 'That said, early signs suggest it doesn't seem to cause more serious illness, but of course, we're still learning more about it.' 'Its spread has been identified in around 22 countries,' said Dr Naveed Asif, GP at The London General Practice. 'The WHO assesses the additional risk to the global public as currently low, and existing Covid-19 vaccines are considered effective in preventing severe disease.' However, the 'Nimbus' variant, as it has been dubbed, does appear to be more transmissible than previous strains, with notable increases reported in India, Hong Kong, Singapore and Thailand, notes Dr Asif. Common symptoms of Nimbus include a severe sore throat, fatigue, mild cough, fever, muscle aches and congestion. It has also been reported that some patients have experienced gastrointestinal symptoms such as nausea and diarrhoea. Healthcare experts have stressed, however, that there is no evidence that the new strain is more deadly or serious than previous variants, and that current Covid vaccines are expected to remain effective and protect anyone infected from severe illness.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store